CN110038157A - 基于聚氨酯的喷射型光固化水凝胶敷料前驱液及制备方法 - Google Patents
基于聚氨酯的喷射型光固化水凝胶敷料前驱液及制备方法 Download PDFInfo
- Publication number
- CN110038157A CN110038157A CN201910342528.XA CN201910342528A CN110038157A CN 110038157 A CN110038157 A CN 110038157A CN 201910342528 A CN201910342528 A CN 201910342528A CN 110038157 A CN110038157 A CN 110038157A
- Authority
- CN
- China
- Prior art keywords
- precursor liquid
- polyurethane
- aerogel dressing
- ejection
- photo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 94
- 239000002243 precursor Substances 0.000 title claims abstract description 76
- 239000004814 polyurethane Substances 0.000 title claims abstract description 67
- 229920002635 polyurethane Polymers 0.000 title claims abstract description 65
- 239000004964 aerogel Substances 0.000 title claims abstract description 36
- 238000000016 photochemical curing Methods 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 58
- 229920000642 polymer Polymers 0.000 claims abstract description 27
- 239000000178 monomer Substances 0.000 claims abstract description 25
- 238000001723 curing Methods 0.000 claims abstract description 15
- 238000005286 illumination Methods 0.000 claims abstract description 11
- 239000000839 emulsion Substances 0.000 claims description 35
- 238000003756 stirring Methods 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 15
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 12
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 239000012948 isocyanate Substances 0.000 claims description 10
- 239000005058 Isophorone diisocyanate Substances 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 150000002009 diols Chemical class 0.000 claims description 9
- NIMLQBUJDJZYEJ-UHFFFAOYSA-N isophorone diisocyanate Chemical compound CC1(C)CC(N=C=O)CC(C)(CN=C=O)C1 NIMLQBUJDJZYEJ-UHFFFAOYSA-N 0.000 claims description 9
- -1 polyoxyethylene Polymers 0.000 claims description 9
- 150000005846 sugar alcohols Polymers 0.000 claims description 9
- 150000002513 isocyanates Chemical class 0.000 claims description 8
- 229920000909 polytetrahydrofuran Polymers 0.000 claims description 8
- 239000012675 alcoholic extract Substances 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- 235000019260 propionic acid Nutrition 0.000 claims description 6
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 6
- 239000004970 Chain extender Substances 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 229920000728 polyester Polymers 0.000 claims description 4
- 229920000570 polyether Polymers 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
- CRVGTESFCCXCTH-UHFFFAOYSA-N methyl diethanolamine Chemical compound OCCN(C)CCO CRVGTESFCCXCTH-UHFFFAOYSA-N 0.000 claims description 3
- 229920000671 polyethylene glycol diacrylate Polymers 0.000 claims description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 229920001610 polycaprolactone Polymers 0.000 claims description 2
- 239000004632 polycaprolactone Substances 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 229920001451 polypropylene glycol Polymers 0.000 claims description 2
- ZXHZWRZAWJVPIC-UHFFFAOYSA-N 1,2-diisocyanatonaphthalene Chemical compound C1=CC=CC2=C(N=C=O)C(N=C=O)=CC=C21 ZXHZWRZAWJVPIC-UHFFFAOYSA-N 0.000 claims 1
- ALQLPWJFHRMHIU-UHFFFAOYSA-N 1,4-diisocyanatobenzene Chemical compound O=C=NC1=CC=C(N=C=O)C=C1 ALQLPWJFHRMHIU-UHFFFAOYSA-N 0.000 claims 1
- 239000005057 Hexamethylene diisocyanate Substances 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 claims 1
- 206010052428 Wound Diseases 0.000 abstract description 51
- 208000027418 Wounds and injury Diseases 0.000 abstract description 51
- 230000035876 healing Effects 0.000 abstract description 7
- 208000014674 injury Diseases 0.000 abstract description 4
- 230000008733 trauma Effects 0.000 abstract description 4
- 238000005213 imbibition Methods 0.000 abstract description 3
- 230000003020 moisturizing effect Effects 0.000 abstract description 3
- 239000000017 hydrogel Substances 0.000 description 52
- 239000000463 material Substances 0.000 description 27
- 238000012360 testing method Methods 0.000 description 17
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 238000004945 emulsification Methods 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 12
- 229920001730 Moisture cure polyurethane Polymers 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 229920002401 polyacrylamide Polymers 0.000 description 9
- 239000008367 deionised water Substances 0.000 description 8
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 238000007711 solidification Methods 0.000 description 8
- 230000008023 solidification Effects 0.000 description 8
- 238000013019 agitation Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 6
- 238000009826 distribution Methods 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 125000000129 anionic group Chemical group 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010039509 Scab Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000003760 hair shine Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N methyl pentane Natural products CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000012644 addition polymerization Methods 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000008473 connective tissue growth Effects 0.000 description 1
- 239000011243 crosslinked material Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- YLHXLHGIAMFFBU-UHFFFAOYSA-N methyl phenylglyoxalate Chemical compound COC(=O)C(=O)C1=CC=CC=C1 YLHXLHGIAMFFBU-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- MPQXHAGKBWFSNV-UHFFFAOYSA-N oxidophosphanium Chemical class [PH3]=O MPQXHAGKBWFSNV-UHFFFAOYSA-N 0.000 description 1
- AUONHKJOIZSQGR-UHFFFAOYSA-N oxophosphane Chemical compound P=O AUONHKJOIZSQGR-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 229920000083 poly(allylamine) Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0085—Porous materials, e.g. foams or sponges
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
- C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F120/52—Amides or imides
- C08F120/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
- C08F120/56—Acrylamide; Methacrylamide
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2/00—Processes of polymerisation
- C08F2/46—Polymerisation initiated by wave energy or particle radiation
- C08F2/48—Polymerisation initiated by wave energy or particle radiation by ultraviolet or visible light
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/08—Processes
- C08G18/0804—Manufacture of polymers containing ionic or ionogenic groups
- C08G18/0819—Manufacture of polymers containing ionic or ionogenic groups containing anionic or anionogenic groups
- C08G18/0823—Manufacture of polymers containing ionic or ionogenic groups containing anionic or anionogenic groups containing carboxylate salt groups or groups forming them
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/30—Low-molecular-weight compounds
- C08G18/32—Polyhydroxy compounds; Polyamines; Hydroxyamines
- C08G18/3271—Hydroxyamines
- C08G18/3275—Hydroxyamines containing two hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/30—Low-molecular-weight compounds
- C08G18/34—Carboxylic acids; Esters thereof with monohydroxyl compounds
- C08G18/348—Hydroxycarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/48—Polyethers
- C08G18/4854—Polyethers containing oxyalkylene groups having four carbon atoms in the alkylene group
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/65—Low-molecular-weight compounds having active hydrogen with high-molecular-weight compounds having active hydrogen
- C08G18/66—Compounds of groups C08G18/42, C08G18/48, or C08G18/52
- C08G18/6666—Compounds of group C08G18/48 or C08G18/52
- C08G18/6692—Compounds of group C08G18/48 or C08G18/52 with compounds of group C08G18/34
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Manufacturing & Machinery (AREA)
- Dispersion Chemistry (AREA)
- Polyurethanes Or Polyureas (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明公开了一种基于聚氨酯的喷射型光固化水凝胶敷料前驱液,该前驱液含有聚氨酯、光固化聚合物单体、光引发剂和水,其中,光引发剂的质量含量为0.5~5%,水的质量含量为50~80%,光固化聚合物单体与聚氨酯的质量比为1.5:1~4:1,前驱液的复数粘度为0.2‑0.8mPa·s,前驱液以液体形态喷涂,经光照固化在皮肤创伤表面形成一层具有伤口适应性的黏附水凝胶敷料,保湿、透气、吸液能力强、力学性能极佳,移除无损,使用方便,而且能够显著促进创伤面的愈合。
Description
技术领域
本发明属于医用材料领域,具体涉及一种基于聚氨酯的喷射型光固化水凝胶敷料前驱液,以及该前驱液的制备方法。
背景技术
皮肤是位于体表、包在肌肉外面的组织,是保持机体内部环境稳定、抵御外来入侵的重要器官,具有物理、化学和生物屏障功能。作为人体最外层的屏障,皮肤往往由于外界各种环境因素受到损伤。烧烫伤、刮擦伤以及外伤引起的大面积溃烂等都严重威胁着人体健康。在中国,每年有高达500~1000万的烧烫伤受害者,其中约5%的病患需要住院治疗。另外,世界卫生组织最新发布的数据称,预计未来在全世界范围内,每年还将有265,000人死于烧伤感染。
创面损伤往往伴随着新陈代谢加剧、水分和蛋白质过度流失、内分泌和免疫系统失调等现象,进而引发各类损伤,如伤口不愈合、压力性溃疡等。因此,研制一种适宜的创面敷料能够即时、有效地控制伤口感染并促进伤口愈合,对于临床伤口护理与康复治疗至关重要。
传统敷料如棉垫、纱布、软麻布等有较强的吸收创面渗液的能力,从而对伤口有一定的保护作用。受限于其材料特性,传统敷料在治疗过程中容易粘连伤口、需要多次更换,且无保湿性,导致其治疗周期长,还往往引起伤口的二次损伤。随着人们对敷料的进一步研究,多种新型敷料逐渐被开发并得以应用。
目前,用于临床治疗的创面敷料主要有以下几种:液体类、喷膜类和水凝胶类等。其中,喷膜型敷料的优点在于其能根据伤口实际情况,通过喷涂成膜在创伤表面形成与其大小尺寸适应并贴合的保护膜,用以抵御细菌的入侵,防止感染。但这类敷料的吸液能力有限,且薄膜易脆,导致其作用时间短。水凝胶是一种含有大量水分的高分子网络材料,其性质柔软,作为创面敷料能够有效吸收伤口渗出液并且保持创面湿润,有效防止伤口表面的脱水和干燥,可以有效缓解病患的不适和疼痛感。但由于皮肤创伤部位形状不规则,预制成型的水凝胶敷料往往难以满足创面的实际需求,较差的组织贴合性直接导致材料与创口表面分离,导致细菌滋生或者感染,进一步带来更大的损伤。理想的创面敷料应该具有如下功能(1)抵御外源性物质的入侵,防止进一步感染;(2)吸收组织渗出液并保持创面环境清洁湿润;(3)与创口表面具有良好的贴合性和适应性;(4)具有一定的机械性能;(5)能与周围正常组织良好粘连。
专利CN107106724A公开了一种包含聚合物、转换引发剂和水状胶体的组合物,该组合物能呈现转换前的液体状态和转换后的粘合剂状态两种形态,液体用于涂在造口皮肤表面,转换成粘合剂状态后将皮肤与造口术器具粘接。但是出于对造口皮肤的健康和粘合剂的形成考虑,这种组合物并不以水为溶剂,而是采用如乙酸乙酯、甲苯、四氢呋喃等有机溶剂溶解聚合物,然后再在一定高温下干燥。专利CN107106724A为制造具有两种状态的施用材料提供了一种可行的案例,但是其材料适合用在无创伤的皮肤表面,起到粘合和保持干燥的功能,无法作为创伤皮肤表面敷料使用,而且有机溶剂残留存在非常大的安全风险,导致临床使用受限。
发明内容
针对现有技术存在的不足,本发明设计了一种基于聚氨酯的喷射型光固化成形的水凝胶敷料前驱液。该前驱液可在喷射过程中实现快速固化,在皮肤创伤表面形成一层具有伤口适应性的黏附水凝胶敷料,保湿、透气、吸液能力强、力学性能极佳,使用方便,而且能够显著促进创伤面的愈合。
本发明的第一方面提供一种基于聚氨酯的喷射型光固化水凝胶敷料前驱液,该前驱液含有聚氨酯、光固化聚合物单体、光引发剂和水,其中,光引发剂的质量含量为0.5~5%,水的质量含量为50~80%,光固化聚合物单体与聚氨酯的质量比为1.5:1~4:1,前驱液的复数粘度为0.2-0.8mPa·s,前驱液以液体形态喷涂,经光照固化形成水凝胶敷料。
水凝胶敷料在使用前以水凝胶前驱液形式保存,通过喷射的方法喷涂于伤口表面形成液膜,在某些波段的光照下,液膜快速固化形成可黏附的水凝胶层。该凝胶无需引入任何粘接剂,聚氨酯的存在赋予了凝胶层自黏附的特性。
在一些实施例中,聚氨酯以水性聚氨酯乳液引入前驱液中。
光固化聚合物单体是指在光引发作用下能发生加成聚合的单体物,包括但不限于丙烯酸、明胶-甲基丙烯酰胺(gelMA)、PEG-二丙烯酸酯(PEGDA)、丙烯酰胺(PAAm)等中的一种或多种。当仅采用这些单体光固化后的聚合物作为敷料的交联材料骨架时,敷料固化形成水凝胶的速度较慢(大于300s以上),这对需要尽快处理创面的患者而言,是极为不利的。经过发明人研究后发现,加入适量的聚氨酯,可以显著缩短固化时间至10-250s,优选的固化时间为30-200s,更优选的固化时间为50-120s。在一些实施例中,发明人还惊奇地发现,引入适当的聚氨酯后,水凝胶的力学性能大为改善,特别是拉伸性能。但是大量的聚氨酯又会影响水凝胶的透明度。因此,将光固化聚合物单体与聚氨酯的质量比设置为1.5:1~4:1,优选为3:1。
前驱液的复数粘度决定着前驱液能否顺利从容器中喷射出去,以及喷射到皮肤的前驱液能否保持附着时的形状进行固化。当粘度过低时,前驱液喷射到皮肤表面后迅速流走,不能形成与创伤的形状和大小匹配的水凝胶。而当粘度过高时,前驱液不能顺利地从容器中喷涂到伤口表面。经过发明人的研究,前驱液的适宜的复数粘度为0.2-0.8mPa·s,更优选的复数粘度为0.3-0.6mPa·s。
前驱液的粘度可以通过光固化聚合物单体与聚氨酯的含量进行调节,但是二者仍需保持在前述的比例范围内,以兼顾合理的固化时间、力学性能和透明度。也可以采用医药上可接受的粘度调节剂进行调节,通常情况下,分子量大的调节剂能够增大粘度,反之,分子量小者降低粘度。
聚氨酯可以通过将含有醇羟基的分子与异氰酸酯反应获得。这些异氰酸酯包括但不限于异佛尔酮二异氰酸酯、甲苯二异氰酸酯、4,4’-二苯基甲基二异氰酸酯、1,6-己烷二异氰酸酯等等。在一些实施例中,采用异佛尔酮二异氰酸酯。含有醇羟基的分子包括聚酯/聚醚的二元醇或多元醇和扩链剂。所述聚酯/聚醚的二元醇或多元醇多元醇选自聚氧化乙烯二元醇、聚四氢呋喃醚二醇、聚氧化丙烯二元醇、聚乳酸二元醇/多元醇、聚己内酯二元醇/多元醇、聚乙交酯二元醇/多元醇中的一种或多种。扩链剂选自1,4-丁二醇、二羟甲基丙酸、三乙醇胺、甲基二乙醇胺中的一种或多种。因为本发明的前驱液使用后将转换为水凝胶,而聚氨酯分子链在分散介质-水中的乳化分散状态将影响聚氨酯乳液的均匀性以及水凝胶的状态。发明人在研究过程中发现,异氰酸酯与含有醇羟基的分子的R值(基团NCO与OH的摩尔比)与聚氨酯乳液的分散状态相关,当R值大于2.5时,聚氨酯分子链在水中大量团聚卷曲并形成微球颗粒,而非乳滴。但是当R值小于1时,固化后的水凝胶弹性模量极低,力学性能差。因此,优选制备聚氨酯的异氰酸酯与含有醇羟基的分子的R值为大于1且小于等于2.5。
在一些实施例中,聚氨酯来源于水乳法制备的水性聚氨酯乳液。本领域的技术人员知晓,当原料或反应物存在一定的酸碱性时,可能对皮肤产生一定的刺激,对这种情况的前驱液,优选其中还含有中和酸碱的pH调节剂,用pH调节剂中和前驱液对乳液的形成也是有利的。pH调节剂可以是无机酸/碱,或者有机酸/碱。
本发明选用水作为分散介质能够实现多重效果,其一,在固化后的水凝胶中大部分水与聚合物材料以结合水的形式存在,沸点>120℃,不会在短时间内挥发,能够保持创伤面周围环境湿润,有助于伤口愈合;其二,含适量水的聚氨酯-光固化聚合物单体固化得到的水凝胶具有特殊的三维网络立体结构,这种结构使皮肤与外界建立小分子交换通道,有助于空气的流通和药物的施用,具有较好的生物相容性,且皮肤湿润但不过度水合;其三,未完全反应的具有生物毒性的异氰酸根(-NCO)能够与水反应生成无毒产物,同时避免有机溶剂存在的安全隐患。因此,本发明的敷料选用含量大于等于50wt%的水为分散介质,但是一些实施例的实验结果表明,水含量越大,溶胀性能降低,而且固化时间也相对延长,因此,本发明的敷料水含量小于等于80wt%。
作为一种优选的实施方式,水凝胶敷料前驱液中还含有药物,所述药物包括但不限于抗菌药、抗炎药、生长因子等中的一种或多种。因为本发明的前驱液固化后的水凝胶敷料具有多孔网络结构,药物填充在这些结构中能够持续地向创伤输送,达到持久的治疗作用。
本发明的前驱液优选光引发剂的吸光范围在紫外光区(250-420nm)或可见光区(400~800nm)。符合这些吸光范围的光引发剂包括但不限于2-羟基-2-甲基-1-[4-(2-羟基乙氧基)苯基]-1-丙酮,2,4,6-三甲基苯甲酰基-二苯基氧化膦,苯甲酰甲酸甲酯,2-二甲氨基-2-苄基-1-[4-(4-吗啉基)苯基]-1-丁酮,氟化二苯基钛茂,双(五氟苯基)钛茂等。
本发明的第二方面提供了前述基于聚氨酯的喷射型光固化水凝胶前驱液的制备方法,该方法包括以下步骤:
(1)用水乳法制备含水量为50~80wt%的水性聚氨酯乳液;
(2)按光固化聚合物单体:聚氨酯=1.5:1~4:1的质量比,加入光固化聚合物单体,搅拌均匀后形成混合乳液;
(3)向上述乳液中加入光引发剂,调整前驱液的含水量保持为50~80wt%,复数粘度为0.2-0.8mPa·s,均匀混合后形成水凝胶前驱液。
本发明的第三个方面提供了前述前驱液的使用方法,包括将前驱液喷涂于创伤表面,暴露在一定波长的光照下形成具有一定厚度的水凝胶敷料。
本发明的有益效果在于:(1)使用前,水凝胶前驱液以液体形式保存,通过喷射的方法喷涂于伤口表面形成液膜,在特定波段的光照下,液膜快速固化形成水凝胶,使用过程便捷;(2)所形成的水凝胶能够有效覆盖创口,与创口形貌完全贴合,进而防止细菌入侵、滋生或感染;(3)水凝胶材料内部含有大量的水分,可保持创伤周围环境湿润;(4)水凝胶可吸收大量的组织液,保证伤口的自清洁;(5)使用完后,水凝胶可直接从皮肤表面无创去除,无二次损伤。
附图说明
图1是本发明实施例1的水性聚氨酯乳液的乳滴粒径分布图;
图2是本发明实施例1的水凝胶敷料前驱液的乳滴粒径分布图;
图3-5是本发明实施例3、对比例1和对比例3制备的PP-50、P-50、PP-42水凝胶敷料的SEM照片;
图6是本发明对比例4制备的R值为3的水凝胶敷料前驱液中微球颗粒的SEM图;
图7是本发明实施例3、4和对比例1、2制备的PP-50、PP-70、P-50、P-70随时间固化状态图;
图8是本发明实施例3、4的前驱液固化的水凝胶的体积和质量溶胀曲线图;
图9是本发明实施例3、4的前驱液固化的水凝胶的拉伸曲线图;
图10是本发明实施例4的PP-70水凝胶在皮肤表面的黏附和剥离图。
具体实施方式
以下通过具体实施例对本发明的发明内容做进一步的阐释,但不应理解为本发明的范围仅限于以下的实例,根据本发明的发明思路和全文内容,可以将以下实例中的各个技术特征做适当的组合/替换/调整/修改等,这对于本领域技术人员而言是显而易见的,仍属于本发明保护的范畴。
实施例1
将13.34g异佛尔酮二异氰酸酯与24g聚四氢呋喃二醇-2000加入装有温度计、回流冷凝管和搅拌器的三口烧瓶(100mL)中,滴加2-3滴辛酸亚锡,在80℃的条件下通氮气混合搅拌3h。然后,降温至50℃,分别将2.4g的2,2-二羟甲基丙酸加入上述反应体系中,保持温度搅拌2h。之后,降温至57℃后继续搅拌0.5~1h,得到聚氨酯预聚体。最后,将2.02g三乙胺加入到97.44g的去离子水中配制乳化中和液。室温下,缓慢将制得的聚氨酯预聚体加入到中和液中,剪切乳化仪高速搅拌2h左右,得到含水量为70wt%的阴离子聚氨酯乳液。乳滴粒径分布15-100nm,如图1所示。
取上述聚氨酯乳液20g,加入90g去离子水和18g丙烯酰胺单体,磁力搅拌1h使其混合均匀。之后,向其中加入2.0g 2-羟基-2-甲基-1-[4-(2-羟基乙氧基)苯基]-1-丙酮,搅拌30min后,装瓶储存于室温中待用。乳滴粒径分布90%集中于26-300nm,如图2所示。
上述聚氨酯-聚丙烯酰胺水凝胶前驱液的含水量为80wt%,R值为2,光固化聚合物单体:聚氨酯为3,复数粘度为0.2mPa·s。
实施例2
将13.34g异佛尔酮二异氰酸酯与24g聚四氢呋喃二醇-2000加入装有温度计、回流冷凝管和搅拌器的三口烧瓶(100mL)中,滴加2-3滴辛酸亚锡,在80℃的条件下通氮气混合搅拌3h。然后,降温至60℃,分别将一定2.14g的甲基二乙醇胺加入上述反应体系中,保持温度搅拌2h。之后,加入适量丙酮(5-20mL)调节反应体系粘度,降温至57℃后继续搅拌0.5~1h,得到PU预聚体。最后,将2.3g乙酸加入到97.44g的去离子水中配制乳化中和液。室温下,缓慢将制得的聚氨酯预聚体加入到中和液中,剪切乳化仪高速搅拌2h左右,得到含水量为70wt%的阳离子聚氨酯乳液。乳滴粒径分布集中于15-100nm之间。。
取上述聚氨酯乳液30g,加入5g去离子水和13.5g丙烯酸单体,磁力搅拌1h使其混合均匀。之后,向其中加入1g 2,4,6-三甲基苯甲酰基-二苯基氧化膦,搅拌30min后,装瓶储存于室温中待用。乳滴粒径分布50~1000nm。
上述聚氨酯-聚丙烯酰胺水凝胶前驱液的含水量为53wt%,R值为2,光固化聚合物单体:聚氨酯为1.5,乳液粘度为0.3mPa·s。
实施例3
将13.34g异佛尔酮二异氰酸酯与24g聚四氢呋喃二醇-2000加入装有温度计、回流冷凝管和搅拌器的三口烧瓶(100mL)中,滴加2-3滴辛酸亚锡,在80℃的条件下通氮气混合搅拌3h。然后,降温至50℃,分别将2.4g的2,2-二羟甲基丙酸加入上述反应体系中,保持温度搅拌2h。之后,降温至57℃后继续搅拌0.5~1h,得到聚氨酯预聚体。最后,将2.02g三乙胺加入到97.44g的去离子水中配制乳化中和液。室温下,缓慢将制得的聚氨酯预聚体加入到中和液中,剪切乳化仪高速搅拌2h左右,得到含水量为70wt%的阴离子聚氨酯乳液。
取上述聚氨酯乳液20g,向其中加入12.4g水,称取18g丙烯酰胺单体分2次加入上述乳液中,室温下磁力搅拌1h。随后加入2.4g 2-羟基-2-甲基-1-[4-(2-羟基乙氧基)苯基]-1-丙酮继续搅拌1h,装瓶储存于室温中待用。乳滴粒径15-500nm。
上述聚氨酯-聚丙烯酰胺水凝胶前驱液的含水量为50wt%,R值为2,光固化聚合物单体:聚氨酯为3,乳液粘度为0.46mPa·s。(记作PP-50)。
将所得前驱液喷出,经365nm光照90s时间后固化得到水凝胶敷料,敷料的SEM照片如图3所示,呈多孔的三维网络立体结构,保湿、透气、自黏附和力学性能好。
实施例4
将13.34g异佛尔酮二异氰酸酯与24g聚四氢呋喃二醇-2000加入装有温度计、回流冷凝管和搅拌器的三口烧瓶(100mL)中,滴加2-3滴辛酸亚锡,在80℃的条件下通氮气混合搅拌3h。然后,降温至50℃,分别将2.4g的2,2-二羟甲基丙酸加入上述反应体系中,保持温度搅拌2h。之后,降温至57℃后继续搅拌0.5~1h,得到聚氨酯预聚体。最后,将2.02g三乙胺加入到97.44g的去离子水中配制乳化中和液。室温下,缓慢将制得的聚氨酯预聚体加入到中和液中,剪切乳化仪高速搅拌2h左右,得到含水量为70wt%的阴离子聚氨酯乳液。
取上述聚氨酯乳液20g,向其中加入47.6g水,称取18g丙烯酰胺单体分2次加入上述乳液中,室温下磁力搅拌1h。随后加入2.4g 2-羟基-2-甲基-1-[4-(2-羟基乙氧基)苯基]-1-丙酮继续搅拌1h,装瓶储存于室温中待用。乳滴粒径集中分布在15-500nm。
上述聚氨酯-聚丙烯酰胺水凝胶前驱液的含水量为70wt%,R值为2,光固化聚合物单体:聚氨酯为3,乳液粘度为0.32mPa·s。(记作PP-70)。
该前驱液固化后得到的水凝胶敷料具有与实施例3类似的三维网络立体结构。
实施例5
在实施例1-5的前驱液中加入抗菌药、抗炎药、生长因子等药物,制得能够携载并缓释活性药物的水凝胶敷料。
对比例1
取24g丙烯酰胺单体在26.4g水中磁力搅拌1h(室温下),随后加入2.4g 2-羟基-2-甲基-1-[4-(2-羟基乙氧基)苯基]-1-丙酮继续搅拌1h,直至其完全溶解并与丙烯酰胺均匀混合形成含水量为50wt%聚丙烯酰胺水凝胶的前驱液(记作P-50)。
将所得前驱液喷出,经365nm光照300s时间后固化得到水凝胶敷料,敷料的SEM照片如图4所示,凝胶结构致密,表面褶皱,无联通的孔洞出现,不利于物质交换。
对比例2
取24g丙烯酰胺单体在61.6g水中磁力搅拌40min(室温下),随后加入2.4g 2-羟基-2-甲基-1-[4-(2-羟基乙氧基)苯基]-1-丙酮继续搅拌1h,直至其完全溶解并与丙烯酰胺均匀混合形成含水量为70wt%聚丙烯酰胺水凝胶的前驱液(记作P-70)。
该前驱液固化后得到的水凝胶敷料具有与对比例1类似的致密结构。
对比例3
将13.34g异佛尔酮二异氰酸酯与24g聚四氢呋喃二醇-2000加入装有温度计、回流冷凝管和搅拌器的三口烧瓶(100mL)中,滴加2-3滴辛酸亚锡,在80℃的条件下通氮气混合搅拌3h。然后,降温至50℃,分别将2.4g的2,2-二羟甲基丙酸加入上述反应体系中,保持温度搅拌2h。之后,降温至57℃后继续搅拌0.5~1h,得到聚氨酯预聚体。最后,将2.02g三乙胺加入到97.44g的去离子水中配制乳化中和液。室温下,缓慢将制得的聚氨酯预聚体加入到中和液中,剪切乳化仪高速搅拌2h左右,得到含水量为70wt%的阴离子聚氨酯乳液。
取上述聚氨酯乳液15g,向其中加入6.8g水,称取18g丙烯酰胺单体分2次加入上述乳液中,室温下磁力搅拌1h。随后加入0.9g 2-羟基-2-甲基-1-[4-(2-羟基乙氧基)苯基]-1-丙酮继续搅拌1h,待其完全溶解并均匀混合后形成含水量为42wt%聚氨酯-聚丙烯酰胺水凝胶前驱液(PP-42)。
将所得前驱液喷出,经365nm光照100s时间后固化得到水凝胶敷料,敷料的SEM照片如图5所示,材料结构致密,表面粗糙,不利于物质的交换。
对比例4
将26.67g异佛尔酮二异氰酸酯与28g聚四氢呋喃二醇-2000加入装有温度计、回流冷凝管和搅拌器的三口烧瓶(100mL)中,滴加2-3滴辛酸亚锡,在80℃的条件下通氮气混合搅拌3h。然后,降温至50℃,分别将3.49g的2,2-二羟甲基丙酸加入上述反应体系中,保持温度搅拌2h。之后,降温至57℃后继续搅拌0.5~1h,得到聚氨酯预聚体。最后,将3.93g三乙胺加入到134.75g的去离子水中配制乳化中和液。室温下,缓慢将制得的聚氨酯预聚体加入到中和液中,剪切乳化仪高速搅拌2h。得到R值为3的前驱液。
该前驱液不能形成分散性好的乳液,在乳化过程中聚氨酯分子链缠结固化形成微球颗粒,其SEM照片如图6所述。
试验例1
按照前述实施例1方法制备含水量为70%,光固化聚合物单体:聚氨酯=3:1,光交联剂含量为5wt%,复数粘度分别为0.1,0.2,0.4,0.6,0.8,1.0mPa·s的敷料液体,复数粘度通过光固化聚合物单体和聚氨酯的总量进行调节,将等量的敷料液装入相同的喷壶(15ml真空型喷雾瓶,商购获得)中,对皮肤表面喷涂,0.1mPa·s的辅料喷涂到皮肤上后迅速流走,固化后的水凝胶形状与伤口匹配度差,也不能稳定地达到需求的厚度。复数黏度为1.0mPa·s的敷料液体喷出时需要较大的按压力,挤出不顺畅。复数黏度为0.2-0.8mPa·s的敷料液体喷涂和固化效果好,特别是0.4,0.6mPa·s效果较佳。
试验例2
将实施例3、对比例1和对比例3的敷料前驱液分别固化后,观察水凝胶的微观形貌。其SEM照片分别如图3、4、5所示,含水量、含PU均会影响水凝胶三维网络立体结构的形成。在水含量50-80%,光固化聚合物单体:聚氨酯质量比为1.5-4:1情况下,水凝胶形成具有贯通孔隙的三维网络立体结构,有利于材料对水分的吸收,以及皮肤与外界小分子(空气、分子药物等)进行交换。
试验例3
用实施例3、4和对比例1、2的水凝胶敷料前驱液做光固化特性研究,考察含水量和聚氨酯对前驱液固化时间的影响。结果如图7所示,其中,P表示只含有丙烯酰胺单体(PAAM),PP表示同时含有丙烯酰胺单体(PAAM)和聚氨酯(PU),后面的数字表示含水量。由图中可以看出,当不含有聚氨酯时,含水量50%和70%的敷料在300s内都无法固化。加入聚氨酯后,敷料在30s可以肉眼观察到固化,完全固化的时间分别是PP-50为62s,PP-70为75s。聚氨酯的加入显著促进了敷料的固化,此外,含水量更高的PP-70所需的固化时间也更长。
试验例4
将实施例3和4的敷料进行一个月的溶胀性能试验,具体实验过程如下:将凝胶前驱液放于固定模具中,光照固化成为尺寸为底面直径(Φ)×高(h)=5×5mm的圆柱体。将上述圆柱体浸泡于PBS溶液中,固定时间称量圆柱体的重量,计算质量溶胀比;同时用游标卡尺测量圆柱体的直径和高度,并计算体积溶胀比。试验结果如图8所示,左图为体积溶胀曲线,右图为质量溶胀曲线。一个月内,溶胀质量比达到原质量的6倍,体积溶胀比接近原体积的8倍,这有利于对创口表面渗出液的吸收,保持伤口表面的自清洁。
试验例5
测试实施例3和4的PU-PAAm前驱液固化后的凝胶材料的弹性模量和拉伸性能。
拉伸性能的测试方法:用万能材料试验机(型号:AGIC 50KN,日本Shimadzu公司)对水凝胶材料拉伸性能进行测试。首先将测试凝胶制成长75mm、宽4mm、厚2mm的哑铃状样条;其次,设置拉伸实验,其中拉伸速率为50mm/min,拉伸载荷10N;最后,将样条固定于夹具中,开始拉伸样条直至样条从中部断裂。
弹性模量的测试方法:使用流变仪(型号:Discovery DHR-2,美国TA公司)对水凝胶的弹性模量进行测试。首先,选择直径20mm的平底不锈钢圆盘为实验夹具,夹具与样品台间距1000μm,将测试凝胶平铺与样品台上;其次,选择时间扫描模式,设置参数应力=1Pa,应变=1%,频率=1Hz,时间=300s。设置好相关参数后,即可开始对材料弹性模量的测试。
测得,该水凝胶的弹性模量范围在103~105Pa。同时用频率扫描模式对材料的稳定性进行测试,发现当频率加到100Hz时,这些凝胶材料的弹性模量和粘性模量并没有发生明显的变化,说明材料在受到外力刺激下结构稳定。
材料的拉伸伸长率可达到原始长度的800~3000%。其中,PP-50水凝胶的伸长率可达900%。而同样弹性模量的PAAm水凝胶的伸长率却只有300%。可见PU还对凝胶的力学性能构成较大影响。
试验例6
测试实施例3和4的固化水凝胶的黏附性能。
以猪皮为基材,测量水凝胶的黏附强度。首先,将猪皮剪切成长(l)×宽(w)=75mm×25mm的长方形样条,将面积为25mm×20mm的水凝胶材料粘在两块待测基底(猪皮)之间。再通过万能材料试验机(型号:AGIC 50KN,日本Shimadzu公司)以5mm/min的速率拉伸样品直至破坏。拉伸曲线如图9所示,两种水凝胶材料与组织均具有良好的黏附性能,其最大黏附强度能达到0.008~0.016MPa。同时可以看出,水含量的增加有利于提高水凝胶的黏附性能。
同时,使用结束后,水凝胶可以无残留地从皮肤上脱离,对皮肤无损伤,例如图10所示的PP-70的水凝胶剥离图。
试验例7
在新西兰大白兔的背部区域构建一个全层皮肤损伤模型(直径Φ=1.5cm),用实施例4中的聚氨酯-聚丙烯酰胺水凝胶对伤口进行处理;没有水凝胶填充的空白伤口作为对照组。具体步骤如下:
实验使用体重约为2000g的成年新西兰大白兔。先用乌拉坦(25wt%,5ml/kg)静脉耳源注射对白兔进行麻醉,并将其背部全部脱毛。然后,在其背部制造直径为1.5cm的圆形全层皮肤缺损伤口模型。其后,将实施例4中的聚氨酯-聚丙烯酰胺水凝胶前驱液(实验组,PP-70)喷洒于伤口表面,紫外灯下短时间固化形成凝胶膜;对照组不做任何处理。术后3天每天给白兔皮下注射青霉素。分别观察0,3,9,17天伤口的愈合情况。
实验现象可观察到3天时,敷了水凝胶材料的伤口(实验组,PP-70)表面干净,无血痂出现,同时有大量肉芽组织长出;而对照组伤口表面有明显的血痂覆盖。说明,水凝胶材料可以有效吸收创口处渗出的组织液,促进创口表面的自清洁。另外,9天时,对照组由于血痂覆盖,使得真皮层结缔组织生长受阻,导致伤口愈合较慢;而敷过水凝胶材料的伤口(实验组,PP-70)大面积愈合,愈合面积明显高于空白组。17天时,敷过水凝胶材料的伤口(实验组,PP-70)已基本愈合,且伤口的疤痕相对较浅;而对照组材料伤口表面长合,但疤痕较深。说明,水凝胶材料的使用能够有效促进皮肤创口的愈合。
Claims (10)
1.一种基于聚氨酯的喷射型光固化水凝胶敷料前驱液,其特征在于,该前驱液含有聚氨酯、光固化聚合物单体、光引发剂和水,其中,光引发剂的质量含量为0.5~5%,水的质量含量为50~80%,光固化聚合物单体与聚氨酯的质量比为1.5:1~4:1,前驱液的复数粘度为0.2-0.8mPa·s,前驱液以液体形态喷涂,经光照固化形成水凝胶敷料。
2.根据权利要求1所述的基于聚氨酯的喷射型光固化水凝胶敷料前驱液,其特征在于,光固化聚合物单体与聚氨酯的质量比为3:1,前驱液的复数粘度为0.3-0.6mPa·s。
3.根据权利要求1所述的基于聚氨酯的喷射型光固化水凝胶敷料前驱液,其特征在于,所述聚氨酯以水性聚氨酯乳液引入前驱液中。
4.根据权利要求3所述的基于聚氨酯的喷射型光固化水凝胶敷料前驱液,其特征在于,所述水性聚氨酯乳液通过含有醇羟基的分子与异氰酸酯用水乳法制备。
5.根据权利要求4所述的基于聚氨酯的喷射型光固化水凝胶敷料前驱液,其特征在于,所述异氰酸酯与含有醇羟基的分子的R值大于1且小于等于2.5。
6.根据权利要求4所述的基于聚氨酯的喷射型光固化水凝胶敷料前驱液,其特征在于,所述异氰酸酯为异佛尔酮二异氰酸酯、甲苯二异氰酸酯、4,4’-二苯基甲基二异氰酸酯、1,6-己烷二异氰酸酯、六亚甲基二异氰酸酯、萘二异氰酸酯、对苯二异氰酸酯中的至少一种,所述光固化聚合物单体选自丙烯酸、明胶-甲基丙烯酰胺、PEG-二丙烯酸酯、丙烯酰胺中的至少一种。
7.根据权利要求4所述的基于聚氨酯的喷射型光固化水凝胶敷料前驱液,其特征在于,所述含有醇羟基的分子包括聚酯/聚醚的二元醇或多元醇和扩链剂,所述聚酯/聚醚的二元醇或多元醇为聚氧化乙烯二元醇、聚四氢呋喃醚二醇、聚氧化丙烯二元醇、聚乳酸二元醇/多元醇、聚己内酯二元醇/多元醇、聚乙交酯二元醇/多元醇中的一种或多种,所述扩链剂为1,4-丁二醇、2,2-二羟甲基丙酸、三乙醇胺、甲基二乙醇胺中的一种或多种。
8.根据权利要求1所述的基于聚氨酯的喷射型光固化水凝胶敷料前驱液,其特征在于,该前驱液中还含有药物,所述药物包括抗炎药物、抗菌药物、生长因子类药物中的一种或多种。
9.如权利要求1-8任意一项所述的基于聚氨酯的喷射型光固化水凝胶敷料前驱液的制备方法,该方法包括以下步骤:
(1)用水乳法制备含水量为50~80wt%的水性聚氨酯乳液;
(2)按光固化聚合物单体:聚氨酯=1.5:1~4:1的质量比,加入光固化聚合物单体,搅拌均匀后形成混合乳液;
(3)向上述乳液中加入光引发剂,调整前驱液的含水量保持为50~80wt%,复数粘度为0.2-0.8mPa·s,均匀混合后形成水凝胶敷料前驱液。
10.如权利要求1-8任意一项所述的基于聚氨酯的喷射型光固化水凝胶敷料前驱液的使用方法,包括将前驱液喷涂于创伤表面,暴露在一定波长的光照下形成具有一定厚度的水凝胶敷料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910342528.XA CN110038157B (zh) | 2019-04-26 | 2019-04-26 | 基于聚氨酯的喷射型光固化水凝胶敷料前驱液及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910342528.XA CN110038157B (zh) | 2019-04-26 | 2019-04-26 | 基于聚氨酯的喷射型光固化水凝胶敷料前驱液及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110038157A true CN110038157A (zh) | 2019-07-23 |
CN110038157B CN110038157B (zh) | 2020-07-14 |
Family
ID=67279500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910342528.XA Expired - Fee Related CN110038157B (zh) | 2019-04-26 | 2019-04-26 | 基于聚氨酯的喷射型光固化水凝胶敷料前驱液及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110038157B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112480350A (zh) * | 2020-11-06 | 2021-03-12 | 中国科学院化学研究所 | 亲水性聚氨酯及其制备方法、生物打印复合材料和应用 |
CN113651924A (zh) * | 2021-08-26 | 2021-11-16 | 北京化工大学 | 光固化聚氨酯丙烯酸酯水凝胶材料及其制备方法和应用 |
CN114479120A (zh) * | 2022-01-25 | 2022-05-13 | 太原理工大学 | 丙烯酸酯改性聚氨酯粘附性水凝胶材料及其制备方法 |
CN116729013A (zh) * | 2023-06-08 | 2023-09-12 | 浙江理工大学 | 一种复合纳米凝胶基紫外监测文身贴及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010017282A1 (en) * | 2008-08-05 | 2010-02-11 | Biomimedica, Inc. | Polyurethane-grafted hydrogels |
CN109354671A (zh) * | 2018-11-08 | 2019-02-19 | 中北大学 | 一种高固含量低黏度水性聚氨酯乳液的制备方法 |
-
2019
- 2019-04-26 CN CN201910342528.XA patent/CN110038157B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010017282A1 (en) * | 2008-08-05 | 2010-02-11 | Biomimedica, Inc. | Polyurethane-grafted hydrogels |
CN109354671A (zh) * | 2018-11-08 | 2019-02-19 | 中北大学 | 一种高固含量低黏度水性聚氨酯乳液的制备方法 |
Non-Patent Citations (1)
Title |
---|
龙立: "UV固化聚氨酯水凝胶的制备及其性能与应用研究", 《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112480350A (zh) * | 2020-11-06 | 2021-03-12 | 中国科学院化学研究所 | 亲水性聚氨酯及其制备方法、生物打印复合材料和应用 |
CN112480350B (zh) * | 2020-11-06 | 2022-04-05 | 中国科学院化学研究所 | 亲水性聚氨酯及其制备方法、生物打印复合材料和应用 |
CN113651924A (zh) * | 2021-08-26 | 2021-11-16 | 北京化工大学 | 光固化聚氨酯丙烯酸酯水凝胶材料及其制备方法和应用 |
CN113651924B (zh) * | 2021-08-26 | 2022-12-30 | 北京化工大学 | 光固化聚氨酯丙烯酸酯水凝胶材料及其制备方法和应用 |
CN114479120A (zh) * | 2022-01-25 | 2022-05-13 | 太原理工大学 | 丙烯酸酯改性聚氨酯粘附性水凝胶材料及其制备方法 |
CN114479120B (zh) * | 2022-01-25 | 2023-06-27 | 太原理工大学 | 丙烯酸酯改性聚氨酯粘附性水凝胶材料及其制备方法 |
CN116729013A (zh) * | 2023-06-08 | 2023-09-12 | 浙江理工大学 | 一种复合纳米凝胶基紫外监测文身贴及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN110038157B (zh) | 2020-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110038157A (zh) | 基于聚氨酯的喷射型光固化水凝胶敷料前驱液及制备方法 | |
KR20120092494A (ko) | 분해 안정화된, 생체 적합성 콜라겐 매트릭스 | |
US6099952A (en) | Medical sponge having mucopolysaccharide coating | |
JPS60150755A (ja) | 合成樹脂製創傷手当用品 | |
TWI597075B (zh) | Hydrophilic polyurethane, hydrophilic polyurethane foam and its preparation Wet wound dressing | |
CN102327161A (zh) | 创伤敷料的制备工艺 | |
KR20160056005A (ko) | 단일 또는 이종의 피부활성성분의 공급제어 기능을 가지는 하이드로겔 마스크팩의 제조방법 | |
CN106474536A (zh) | 一种用于战创伤的液体绷带 | |
CN101879324A (zh) | 壳聚糖复合医用敷料的制备方法 | |
CN103976887A (zh) | 一种凝胶面膜基质及其制备工艺 | |
CN113082286A (zh) | 一种基于3d打印技术的三层仿生皮肤支架及其制备方法 | |
CN111282015B (zh) | 一种人工皮肤除疤贴 | |
TW200803924A (en) | A sheet device comprising bio-cellulose for alleviating skin damage and relieving skin problem | |
CN106102513B (zh) | 皮肤遮蔽材料 | |
Chvapil et al. | Lanolin and epidermal growth factor in healing of partial-thickness pig wounds | |
CN105056279A (zh) | 一种复合胶原的聚氨酯基双层敷料 | |
CN103431947B (zh) | 敷料 | |
CN101797376A (zh) | 改性胶原蛋白膜的制备方法 | |
WO2020215297A1 (zh) | 基于聚氨酯的喷射型光固化水凝胶敷料前驱液及制备方法 | |
CN102327639A (zh) | 一种创伤敷料的制备工艺 | |
CN205832004U (zh) | 一种贴覆结构 | |
CN109562135A (zh) | 基于Sedum telephium植物的叶子制备用于治疗感染的甲癣指甲的产品的方法 | |
WO2022226857A1 (zh) | 一种用于刺青护色的湿式敷料及其使用方法 | |
CN115975185B (zh) | 一种含多肽的可溶性微针贴及其制备方法 | |
RU2320349C1 (ru) | Способ лечения ожоговых ран |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200714 |